Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in advanced non-small cell lung cancer
ISRCTN80153848Phase 3Completed
- Sponsor
- University of Birmingham
- Start
- Apr 2005
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of gemcitabine, cisplatin and carboplatin in non-small cell lung cancer (NSCLC) (3 arms), sponsored by University of Birmingham. Primary endpoint: Overall survival. Started Apr 2005; status: completed.
02
Drugs
gemcitabinecisplatincarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ISRCTN80153848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN80153848.